Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AZ's Oral PCSK9 Inhibitor halves Bad Cholesterol in Phase 2
Details : AZD0780 is an oral, small molecule PCSK9 inhibitor that is being developed by AstraZeneca as an innovative therapy for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels.
Product Name : AZD0780
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SolasCure Enrols First Patient in Phase 2 Trial for Aurase Wound Gel
Details : Aurase Wound Gel is a hydrogel releasing Tarumase, a recombinant enzyme that selectively targets fibrin, collagen & elastin in wounds to promote healing through debridement.
Product Name : Aurase Wound Gel
Product Type : Enzyme
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silence's Zerlasiran Shows Positive 48-week Phase 2 Data
Details : SLN360 (zerlasiran) is a siRNA designed to lower the body’s production of Lp(a), it is being investigated in patients having risk of atherosclerotic cardiovascular disease (ASCVD) events.
Product Name : SLN360
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 20, 2024
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : 5Am Ventures
Deal Size : $120.0 million
Deal Type : Private Placement
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
Details : The company intends to use the net proceeds for the advancement of its ongoing clinical development for SLN360 (zerlasiran) for the treatment of atherosclerotic cardiovascular disease.
Product Name : SLN360
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 02, 2024
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : 5Am Ventures
Deal Size : $120.0 million
Deal Type : Private Placement
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silence Reports Positive 36-Week Data from Phase 2 Study of Zerlasiran
Details : SLN360 (zerlasiran) is a phase 2 siRNA designed to reduce Lp(a) production, a genetic risk factor for cardiovascular disease affecting 20% of the population.
Product Name : SLN360
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 13, 2024
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SolasCure Demonstrates Proof-of-Concept in Phase lla Safety Trial of Aurase Wound Gel
Details : Aurase is an enzyme analogue large molecule drug candidate, which is currently being evaluated for the treatment of patients suffering from chronic venous leg ulcer.
Product Name : Aurase
Product Type : Enzyme
Upfront Cash : Inapplicable
December 12, 2023
Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
Details : SLN360 is a gene ‘silencing’ therapy, designed to temporarily blocks LPA, a gene that tells the body to make a specific protein that is only found in Lp(a). As the levels of Lp(a) are lowered, which lowers the risk of heart diseases, heart attacks an...
Product Name : SLN360
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SLN360 (zerlasiran) is a siRNA (short interfering RNA) designed to lower the body’s production of lipoprotein(a), a key genetic risk factor for cardiovascular disease.
Product Name : SLN360
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 11, 2023
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SLN360, is gene silencing therapy – one that is designed to temporarily block a specific gene’s message that would otherwise trigger an unwanted effect.In this case, it aims to ‘silence’ LPA, a gene that tells body to make a specific protein that...
Product Name : SLN360
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ION449
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive results from the ETESIAN Phase IIb trial showed AZD8233 met the primary endpoint at 50 mg with 73% (95% confidence interval [CI]: -77%, -68%) reduction in low-density lipoprotein cholesterol (LDL-C) levels, from baseline.
Product Name : AZD8233
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : ION449
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable